Cardiomyopathy laboratory findings

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy laboratory findings

CDC on Cardiomyopathy laboratory findings

Cardiomyopathy laboratory findings in the news

Blogs on Cardiomyopathy laboratory findings

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]

## Overview

[edit | edit source]

Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome. Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.

## Cardiomyopathy Laboratory Findings

[edit | edit source]

* Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure.[1]
* Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome.[1]
* Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
* Elevated troponin levels indicate ischemic heart disease, and should be investigated as much, till coronary arterial disease is ruled out.
* Elevated iron saturation and ferritin are indicative of hemochromatosis as a cause of cardiomyopathy.

## References

[edit | edit source]

1. ↑ 1.0 1.1 Sisakian H (June 2014). "Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies". World J Cardiol. 6 (6): 478–94. doi:10.4330/wjc.v6.i6.478. PMID 24976920.

Template:WH Template:WS